Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    87,904.66
    +1,083.70 (+1.25%)
     

  • CMC Crypto 200

    1,367.36
    +54.73 (+4.17%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Onconova Therapeutics and Pluristem Therapeutics Surge as Candidate Drugs Move Closer to Final Approval

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / April 5, 2017 / Onconova scored a 2-for-1 with its FDA candidate drug trials and Pluristem is on the cusp of their drug potentially having a broad military and national application. Both stocks are currently selling under $4 per share.

RDI Initiates Coverage:

Onconova Therapeutics Inc. https://ub.rdinvesting.com/news/?ticker=ONTX

Pluristem Therapeutics Inc. https://ub.rdinvesting.com/news/?ticker=PSTI

Onconova Therapeutics advanced 6.98% to close at $3.22 a share on Tuesday. The stock traded between $3.22 and $3.88 on volume of 4,247,228 shares traded. Onconova rose by as much as 18% in premarket trading. On Tuesday, the company reported both of its cancer treatment drugs returned positive pre-clinical results. It presented the data at the annual meeting of the American Association of Cancer Research (AACR). The company's 3rd Generation Oral CDK4/6 + ARK5 Inhibitor drug and dual FLT3 and Src inhibitor drug both showed positive endpoint results.

ADVERTISEMENT

The company reported revenues of $5.546 million for the year ending December 31, 2016, with a net operating loss of more than $23 million for the same period. It reported a cash flow of just over $21 million at the end of its fiscal year, ending December 31st.

Access RDI's Onconova Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=ONTX

Pluristem Therapeutics advanced 8.89% to close at $1.47 a share on Tuesday. The stock traded between $1.36 and $1.54 on volume of 1,700,886 shares traded. Pluristem, a biotech company that focuses on cell therapy, could be positioned to take advantage of the proposed increase in defense spending as its acute radiation syndrome (ARS) antidote moves closer towards FDA approval. The danger of ARS is that exposure to high doses of radiation to the body in a very short period of time damages bone marrow, making the creation of red blood cells nearly impossible. The company's PLX-R18 drug demonstrated a 100% recovery rate in animals when treated with PLX-R18. In comparison, the placebo group had only a 30% recovery rate. After treatment with PLX-R18, the animal's blood cell production returned to normal in less than 48 hours of injection.

Access RDI's Pluristem Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=PSTI

Our Actionable Research on Onconova Therapeutics Inc. (NASDAQ: ONTX) and Pluristem Therapeutics Inc. (NASDAQ: PSTI) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com